Home / Health / New Urine Test Detects Bladder Cancer With 95% Accuracy
New Urine Test Detects Bladder Cancer With 95% Accuracy
2 Oct
Summary
- New urine test achieves 95% accuracy in detecting bladder cancer.
- The test analyzes RNA from tumor cells, offering treatment insights.
- RNA analysis may predict patient response to BCG immunotherapy treatment.
A new urine test developed at Stanford University, known as uRARE-seq, shows remarkable promise in diagnosing bladder cancer with 95% accuracy, potentially outperforming existing methods.
The innovative test measures RNA messages from tumor cells in urine, offering a more detailed understanding of cancer aggressiveness and treatment effectiveness.
This RNA analysis not only aids in early detection but also analyzes tumor biology and immune activity, potentially predicting patient response to therapies like BCG immunotherapy. Patients with specific RNA signatures indicating immune response are more likely to benefit from BCG.
Published in Nature Medicine on October 2, 2026, the study reviewed nearly 700 urine samples. The test correctly identified cancer indications in 95% of patients and healthy individuals in 90% of cases.
It can detect even early, non-muscle invasive bladder cancers. The test also identified residual disease post-surgery and BCG treatment. Identifying T-cell signatures in urine could guide treatment selections, potentially sparing some patients from less effective therapies.
Researchers also presented early evidence that urine RNA analysis may be useful for kidney and prostate cancers. These findings, while promising, require replication in future studies before routine clinical use.
